Drug Profile
Research programme: neonatal compartment syndrome preventative therapy - Diomune
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Diomune
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscle injury
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Muscle injury(In neonates, Prevention) in Spain
- 11 Aug 2016 Early research in Muscle injury (Prevention, In neonates) in Spain (unspecified route)